Lack of protease inhibitor resistance following treatment failure - Too good to be true?

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3704-3705

  Bartlett, John A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EMTRICITABINE; METHAMPHETAMINE; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPING TECHNIQUE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICATION COMPLIANCE; METHAMPHETAMINE DEPENDENCE; PRIORITY JOURNAL; PSYCHOSOCIAL REHABILITATION;

DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS;

EID: 84883527034     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71784     Document Type: Article

References (8)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in the treatment of HIV-1-infected adults and adolescents. Department of Health and Human Services Web site. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 27, 2013.
2. Kempf D, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Inf Dis. 2004;189(1):51-60. View this article via: PubMed CrossRef (Pubitemid 38122329)
3. Eron J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet. 2006;368(9534):476-482. View this article via: PubMed CrossRef (Pubitemid 44160731)
4. Riddler S, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106. View this article via: PubMed CrossRef (Pubitemid 351679596)
5. Daar E, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445-456. View this article via: PubMed CrossRef
6. Bartlett J, et al. Minimizing resistance consequences after virologic failure on initial combination therapy. J Acquir Immune Defic Syndr. 2006;41(3):323-331. View this article via: PubMed
7. Rabi SA, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest.doi:10.1172/JCI67399 View this article via: CrossRef
8. Côté HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol. 2001;75(2):589-594. View this article via: PubMed CrossRef (Pubitemid 32037261)